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Amedication error is defined as any preventable event that may cause or lead to in-
appropriate medication use or patient harm while the medication is in the control of the
health care professional, patient and consumer (1).
Such events may be related to the professional practice, health care products, proce-
dures, and systems, including prescribing, order communication, product labeling, pa-
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The aims of this prospective study were to determine the
incidence and types of prescribing medication errors and
ways to prevent them from reaching patients. Data were
collected from 4951 prescriptions over a 25 week period
in 2002. Medication errors were classified as: incorrect
dose, incorrect dose interval, duplication of therapy and
drug interactions. The medical record analysis was used
to compare prescribing with Croatian literature drug data
and AHFS first Web version 2 (American Society of Health
System Pharmacists). The incidence of medication errors
in the entire sample, including all potential drug interac-
tions, was 14.7%. However, as only 8 interactions (out of
356 potentially possible interactions) were assessed as
clinically significant, then the total number of all types
of medication errors was 379. This resulted in an inci-
dence of 7.7%. Dosage errors were the most frequent er-
rors, followed by incorrect interval, drug duplication and
drug interaction. The difference between the incidence
of potentially possible and clinically significant drug in-
teractions was quite large (7.2 vs. 0.2%). Thus, a critical
attitude is necessary when evaluating available data on
drug interactions. Our findings point to the need of sys-
tematic control of prescribed therapies, which could be
ensured by the application of the Unit Dose Drug Distri-
bution System. A medication errors reporting program
should be established both at the hospital and at natio-
nal levels in Croatia.
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ckaging, and nomenclature compounding, dispensing distribution, administration, edu-
cation, monitoring and use (2–6).
We distinguish between errors in the planning (»mistakes«) and errors in the execu-
tion of the act (»slips«). Slips result from distractions or failure to pay attention at critical
moments. Mistakes are more complex and include the rules based on mistakes and know-
ledge. They arise because of lack of knowledge or because of misinterpretation of the
problem.
The Institute for Safe Medication Practices (ISMP) was established in 1994 in the
USA as a non-profit organization that works closely with practitioners, regulatory agen-
cies, health care institutions, professional organizations and the pharmaceutical industry
to provide education about adverse drug events. In 1995, the USP spearheaded the for-
mation of the National Coordinating Council for Medication Error Reporting and Pre-
vention (NCCMERP). Leading national health care organizations are for the first time,
meeting, collaborating and cooperating to address the interdisciplinary causes of errors
and to promote the safe use of medications.
NCCMERP has reviewed thousands of reports of medication errors. In all cases, the
causes are multifactorial, cutting across many lines of responsibility.
Leape and co-workers (7) define broad categories or domains, describing the under-
lying problems that result in medication errors. They found that 56% of the cases they
detected were due to prescription errors and 44% involved delivery and administration.
A comprehensive examination of adverse drug events in two large academic long-
term care facilities (8) reports their incidence of 9.8%. Nearly 42% of the observed cases
were assessed as preventable. Study findings reinforce the need for a special focus on the
ordering and monitoring stages of pharmaceutical care for preventing medication errors.
Medication error can be recognized and used to help prevent future errors. Methods
of medication error analysis provide models for the detection and reduction of acci-
dents. Investigations of medication errors have contributed to reducing the rate of their
incidence.
The objective of this study was to determine the incidence of medication errors, to
identify the types of prescribing medication errors in order to improve the present system
of drug distribution in the hospital (floor stock system) by changing to the Unit Dose
Drug Distribution System (UDDDS). Thus, clinical pharmacists will be directly involved
in the control of prescribed therapy and able to promptly perceive a prescribing error,




The occurrence of medication errors was analyzed in a prospective study of pre-
scriptions during a period of 25 weeks in 2002 in different wards of the Clinic of Internal
Medicine (Dubrava University Hospital, Zagreb). Patient records were randomly selec-
ted and evaluated by a blind process involving a pharmacist and a physician. The pre-
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scribed therapy was controlled with regard to drug dose and dosing interval, according
to official drug data, duplication of drugs based on their association with the therapeutic
drug class, interactions and, separately, clinically significant interactions classified accor-
ding to AHFS first Web version 2 (9). A total of 4951 randomly chosen medical records
for 1303 patients, aged from 20 to 78 years, were examined. Of the total number, 33% of
the patients were female and 67% male. The patients were hospitalized for 10.4 days on
average. The average number of prescribed drugs per patient amounted to 3.8.
Database for monitoring medication errors
Data for monitoring medication errors were taken from the database of drugs AHFS
first Web version 2 (9), Pharmacotherapy manual 3 (10) and Register of Drugs in Croatia
(11). The prescribed therapy is listed according to generic names of drugs in the »drug
profile« – AHFS first (9), which enables rapid screening of possible significant interac-
tions, classified in three categories according to the severity level: 1 – contraindicated,
meaning that the particular drug combination is clearly contraindicated in all cases and
should not be dispensed or administered to the same patient, 2 – severe interaction,
meaning that action is required to reduce the risk of a severe adverse reaction, and 3 –
moderate interaction, meaning to assess the risk to the patient and take action as needed.
Results are expressed as percentage of the confirmed medication errors in relation
to the total number of prescribed drugs (prescriptions).
RESULTS AND DISCUSSION
Prescribed therapy was investigated in a prospective study with regard to drug dos-
age, dosing interval, therapy duplication and possible interactions of the prescribed
drugs due to simultaneous application of another drug. Table I shows the medication er-
rors determined, expressed as the number of occurrences and the percentage in relation
to the total number of prescriptions. Fig. 1. shows the share of specific medication errors
in relation to the total number of medication errors. The share of medication errors ac-
cording to pharmacotherapeutic groups is presented in Fig. 2. The largest share of medi-
cation errors was involved drugs in group C, acting on the cardiovascular system, and
159
V. Ba~i} Vrca et al.: Prescribing medication errors in hospitalised patients: A prospective study, Acta Pharm. 55 (2005) 157–167.



















168 134 69 356/8 727/379
Incidence
(%)
3.4 2.7 1.4 7.2/0.2 14.7/7.7
in group J, anti-infective drugs according to the Anatomical Therapeutic Chemical (ATC)
classification of drugs, which is partly proportional to the participation of individual
groups of drugs in the total drug consumption expressed in defined daily doses (DDD)
per 100 hospital days (Fig. 3).
Table II shows the relation between age of hospitalized patients, share of prescrip-
tions and share of medication errors. Data in Table II show a larger share of older pa-
tients in the number of prescriptions, and consequently a higher incidence of medication
errors.
The incidence of incorrect drug doses was 3.4% (or 168 cases) of the total number of
prescriptions (4951). 29% of the incorrectly prescribed drug doses were overdosed, while
71% were underdosed. About 50% of the errors connected with drug dosing referred to
antibiotics, most frequently underdosed.
The incidence of incorrect dosing intervals was 2.7% (134 cases) of the total number of
prescriptions. In more than 14% of those cases the dosing interval was not recorded at all!
During the study, prescribing of drugs from the same pharmacotherapeutic groups
(duplication of therapy) was observed in 69 cases, or 1.4% of the total number of pre-
scriptions. The most frequent simultaneously prescribed drugs were calcium channel
blockers, e.g. nifedipine and verapamil. Frequent duplication of therapy with non-ste-
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Fig. 1. Share of certain types of prescribing
medication errors, including clinically sig-
nificant drug interactions only (A) and all




















B C J N R Other
Group
Fig. 2. Share of observed medication errors
in relation to the groups of ATC-classifica-
tion of drugs: B – blood and blood forming
organs, C – cardiovascular system, J – anti-
infectives for systemic use, N – nervous sys-
tem, R – respiratory system, other – other
groups.
roid anti-inflamatory drugs (NSAIDs) was also observed (ketoprofen, diclofenac and in-
domethacin were simultaneously prescribed).
According to refs. 10 and 11, all potential drug interactions amounted to 356 or 7.2%
of the total number of medication errors. According to more selective criteria of AHFS
first (a), only 8 drug interactions or 2.3% of the 356 can be classified as clinically signifi-
cant. Out of them 7 interactions were of severity level – 2 and one interaction of severity
level – 3. The share of clinically significant interactions in the total number of medication
errors amounted to 0.2% (Table I).
The incidence of medication errors in the entire sample, including all potential drug
interactions, was 14.7%; one medication error occurred per each 6–7 prescriptions. How-
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A B C H J L M N R Other
Group
Fig. 3. Total drug consumption, expressed as defined daily doses (DDD) per 100 hospital days (Cli-
nic of Internal Medicine, Dubrava University Hospital, Zagreb, Croatia, 2002): A – alimentary tract
and metabolism, B – blood and blood forming organs, C – cardiovascular system, H – systemic hor-
monal preparations, J – antiinfectives for systemic use, L – antineoplastics and immunostimulating
agents, M – musculo-sceletal system, N – nervous system, R – respiratory system, Other – other
groups.
Table II. Share of hospitalized patients, number of prescriptions and medication errors according to












20–30 2.2 0.9 0.1
31–40 4.3 3.1 1.2
41–50 20.6 18.1 2.4
51–60 21.5 24.3 25.6
61–70 31.3 34.6 38.6
71–78 20.1 19.1 32.1
ever, if only 8 interactions (out of 356 potentially possible interactions) were judged to
be clinically significant, then the total number of all types of medication errors was 379.
This resulted in an incidence of 7.7%, or one medication error per each 13 prescriptions
(Table I). Certain types of prescribing medication errors significantly differed, as did the
significance of those errors (Fig. 1).
The difference between the theoretically possible and clinically significant interac-
tions is large and can be the cause of unnecessary over-interventions. Thus, a critical at-
titude is necessary when evaluating data on drug interactions. Use of relevant databases
that enable rapid screening can greatly facilitate the daily practice of the clinical phar-
macist in targeting interventions appropriately.
The problem of accurately estimating the incidence of drug interactions, particu-
larly of distinguishing between clinically significant and non-significant, is well known.
The results with regard to incidence differ, mainly because published studies have fre-
quently used different criteria definition. Although the overall incidence of significant
drug interactions is probably low (< 1%), it is still a considerable problem in terms of the
global number of patients at risk and potential harmful consequences (12). Drug interac-
tions can be pharmacokinetic or pharmacodynamic. Pharmacodynamic interactions are
much less easy to predict and classify than those with a pharmacokinetic basis, which
can be anticipated, though their extent is less easily predicted. Knowledge of drug inter-
actions is an important parameter of rational pharmacotherapy.
The observed clinically significant interactions are shown in Table III. In all cases
the prescribed therapy was corrected and/or the patients were more closely monitored.
Patients in the older age groups take more drugs simultaneously, which significant-
ly increases the possibility of medication errors. The largest share of medication errors
(38.6 %) was recorded in the group of patients aged from 61 to 70 years (Table II). More-
over, half of all observed clinically significant drug interactions were connected with the
same group of patients. Elderly patients were the most endangered group of patients in
that sense.
The results of this study concur with the literature data and indicate that systematic
control of prescribed therapy is necessary. This is important because there is no serious
publication about the existence of medication errors in Croatia. We began to carefully
talk about it only a few years ago. Publication of medication errors would not have been
possible 30 years ago anywhere in the world. There seemed to be a certain fatalism that
medication errors were an inevitable by-product of patient care. No one had added up
their number; no one had begun to categorize the types of errors; no one had recognized
the immense learning and improvement opportunities. Medication errors were about
the courage and intellectual curiosity of individuals who did not accept medication er-
rors as inevitabilities and believed that improved systems and individual caregiver sup-
port could produce safer patient care.
Our findings point to the need of systematic control of prescribed therapies. This
could be ensured by the application of the UDDDS in the hospital, because this system,
contrary to the traditional floor stock system widely used in Croatian hospitals, directly
involves clinical pharmacists in the medication process. Professional obligations of clini-
cal pharmacists should include the control of prescribed therapy. The UDDDS, especial-
ly with computerized prescribing, would be justified in order to avoid medication er-
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rors, both at the level of prescribing or administration (35, 36). It is imperative for phar-
macists to cooperate with physicians, nurses and patients. Teamwork is fundamental to
the effective medication error prevention system.
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tain, but decreases in
volume of distribu-
tion as well as renal
and metabolic clear-
ance of digoxin have
been observed.
Co-administration of
these drugs may re-











Propafenone should be used
with caution in patients with
serous structural heart disease.
Serum digoxin levels should be
monitored and patients should
be observed for signs of
digoxin toxicity and digoxin


















level depresses the si-
nus node, resulting in
bradycardia, and pro-
duces other signs of
toxicity. Magnitude of




Serum digoxin levels should be
monitored and patients should
be observed for symptoms of
digoxin toxicity and the dosage






duce the clearance of
digoxin and may
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ing sites. Co-admin-
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and low heart rate.
Serum digoxin level should be
monitored and patients should
be observed for symptoms of
toxicity and the dosage should
be adjusted accordingly. Incre-
ased concentrations may occur














levels may result in
theophylline toxicity.
Serum theophylline levels
should be monitored and the
dosage may need to be de-
creased.
CONCLUSIONS
The difference between the incidence of theoretically possible and clinically signifi-
cant drug interactions is quite large (7.2 vs. 0.2%) and can be the cause of unnecessary
over-interventions. Thus, a critical attitude is necessary when evaluating the data on
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serum levels may re-
sult in an increase in
the clinical effects of
the anticoagulant and
an increased risk of
bleeding.
Prothrombin activity should be
carefully monitored and the
dose of warfarin should be ad-
justed as needed. Some re-
searchers recommend reducing
the initial anticogulant dose by
25 to 50%. It may take several
weeks of concurrent therapy
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ble severe or perma-
nent hearing loss.
Hearing function should be
monitored. High dosages,
paricularly in patients with im-
paired renal function should be
avoided. This interaction is
likely to occur, although clini-












of the antifungal may
be reduced.
Concurrent administration of
ranitidine and cimetidine with
azole antifungal drugs should
be avoided. An interaction can






















Concurrent therapy of these
drugs, including other
NSAIDs, should be avoided. If
these drugs are used concur-
rently, renal function and se-
rum electrolytes should be
monitored.
2 – severe interaction, 3 – moderate interaction
Table III. continued
drug interactions. Use of relevant databases that enable rapid screening can greatly faci-
litate the daily practice of the clinical pharmacist.
Our findings point to the need of systematic control of prescribed therapies which
could be ensured by the application of the UDDDS in the hospital.
A painful method of error prevention is to learn from previous errors. It is impor-
tant to take into account the potential risks of future errors, as well as to acquire infor-
mation on errors that have previously occurred. A medication errors reporting program
should be established, both at the hospital and national levels in Croatia, enabling sys-
tematic data collection and sharing the information about medication errors in order to
prevent and reduce their incidence in the future.
REFERENCES
1. M. R. Cohen, Medication Errors, American Pharmaceutical Association, Washington D.C. 1999,
pp. 2.1–2.4.
2. M. F. Conlan, Medical errors, Hosp. Pharm. Rep. 14 (2000) 41–44.
3. M. A. Sweeney, Physician-pharmacist collaboration: a millennial paradigm to reduce medica-
tion errors, J. Am. Osteopath. Assoc. 102 (2002) 678–681.
4. N. M. LaPointe and J. G. Jollis, Medication errors in hospitalized cardiovascular patients, Arch.
Intern. Med. 163 (2003) 1461–1466.
5. M. L. Jenkinson, Prescribing errors, Lancet 360 (2002) 256–259.
6. S. Hennessy, W. B. Bilker, L. Zhou, A. L. Weber, C. Brensinger, Y. Wang and B. L. Strom, Retro-
spective drug utilization review, prescribing errors, and clinical outcomes, JAMA 290 (2003)
1494–1499.
7. L. L. Leape, D. W. Bates and D. J. Cullen, System analysis of adverse drug events, JAMA 274
(1995) 35–43.
8. J. H. Gurwitz, T. S. Field, J. Judge, P. Rochon, L. R. Harrold, C. Cadoret, M. Lee, K. White, J.
LaPrino, J. Erramuspe-Mainard, M. DeFlorio, L. Gavendo, J. Auger and D. W. Bates, The inci-
dence of the adverse drug events in two large academic long-term care facilities, Am. J. Med. 118
(2005) 251–258.
9. AHFS first Web version 2, American Society of Health System Pharmacists, Indianapolis 2002.
10. B. Vrhovac and @. Reiner, Farmakoterapijski priru~nik 3, Med-Ekon, Zagreb 2000.
11. L. Bencari}, Register of Drugs in Croatia, 45th ed., Healthcare Employers, Zagreb 2002.
12. A. Lee, I. H. Stockley, Drug Interactions, in Clinical Pharmacy and Therapeutics, 3rd ed. (Eds. R.
Walker and C. Edwards) Edinburgh 2003 pp. 21–32.
13. G. G. Belz, W. Doering, R. Munkes and J. Matthews, Interaction between digoxin and calcium
antagonists and antiarrhythmic drugs, Clin. Pharmacol. Ther. 33 (1983) 410–417.
14. M. V. Calvo, A. Martin Suarez M. C. Avila and C. Martin Luengo, Digoxin-propafenone interac-
tion, Med. Clin. (Barcelona) 89 (1987) 171–172.
15. J. O. Moysey, N. S. Jaggarao, E. N. Grundy and D. A. Chamberlain, Amiodarone increases plas-
ma digoxin concentrations, Br. Med. J. 282 (1981) 272–275.
16. P. Douste-Blazy, J. L. Montastruc, B. Bonnet, P. Auriol, D. Conte and P. Bernadet, Influence of
amiodarone on plasma and urine digoxin concentrations, Lancet 1 (1984) 905–907.
17. K. E. Pedersen, A. Dorph-Pedersen, S. Hvidt, N. A. Klitgaard and F. Nielsen-Kudsk, Digoxin-
verapamil interaction, Clin. Pharmacol. Ther. 30 (1981) 311–316.
165
V. Ba~i} Vrca et al.: Prescribing medication errors in hospitalised patients: A prospective study, Acta Pharm. 55 (2005) 157–167.
18. H. O. Klein, R. Lang, E. Weiss, E. Di Segni, C. Libhaber, J. Guerrero and E. Kaplinsky, The influ-
ence of verapamil on serum digoxin concentration, Circulation 65 (1982) 998–1003.
19. H. O. Klein and E. Kaplinsky, Verapamil and digoxin: their respective effects on atrial fibrilla-
tion and their interaction, Am. J. Cardiol. 50 (1982) 894–902.
20. R. L. Manfredi and E. S. Vesell, Inhibition of theophylline metabolism by long-term allopurinol
administration, Clin. Pharmacol. Ther. 29 (1981) 224–229.
21. M. Barry and J. Feely, Allopurinol influences aminophenazone elimination, Clin. Pharmacokin.
19 (1990) 167–169.
22. J. J. Grygiel, L. M. Wing, J. Farkas and D. J. Birkett, Effects of allopurinol on theophylline metab-
olism and clearance, Clin. Pharmacol. Ther. 26 (1979) 660–667.
23. S. Vozeh, J. R. Powell, G. C. Cupit, S. Riegelman and L. B. Sheiner, Influence of allopurinol on
theophylline disposition in adults, Clin. Pharmacol. Ther. 27 (1980) 194–197.
24. S. Almog, N. Shafran, H. Halkin, P. Weiss, Z. Farfel, U. Martinowitz and H. Bank, Mechanism of
warfarin potentiation by amiodarone: dose-and concentration-dependent inhibition of warfarin
elimination, Eur. J. Clin. Pharmacol. 28 (1985) 257–261.
25. A. Rees, J. J. Dalal, P. G. Reid, A. H. Henderson and M. J. Lewis, Dangers of amiodarone and an-
ticoagulant treatment, Br. Med. J. (Clin. Res. Ed.) 282 (1981) 1756–1757.
26. R. A. O'Reilly, W. F. Trager, A. E. Rettie and D. A. Goulart, Interaction of amiodarone with race-
mic warfarin and its separated enantiomorphs in humans, Clin. Pharmacol. Ther. 42 (1987) 290–
294.
27. L. D. Heimark, L. Wienkers, K. Kunze, M. Gibaldi, A. C. Eddy, W. F. Trager, R. A. O'Reilly and
D. A. Goulart, The mechanism of the interaction between amiodarone and warfarin in humans,
Clin. Pharmacol. Ther. 51 (1992) 398–407.
28. R. H. Mathog and W. J. Klein, Jr., Ototoxicity of ethacrynic acid and aminoglycoside antibiotics
in uremia, N. Engl. J. Med. 280 (1969) 1223–1224.
29. W. D. Meriwether, R. J. Mangi and A. A. Serpick, Deafness following standard intravenous dose
of ethacrynic acid, JAMA 216 (1971) 795–798.
30. S. C. Piscitelli, T. F. Goss, J. H. Wilton, D. T. D'Andrea, H. Goldstein and J. J. Schentag, Effects of
ranitidine and sucralfate on ketoconazole bioavailability, Antimicrob. Agents Chemother. 35 (1991)
1765–1771.
31. S. G. Lim, A. M. Sawyerr, M. Hudson, J. Sercombe and R. E. Pounder, Short report: the absorp-
tion of fluconazole and itraconazole under conditions of low intragastric acidity, Aliment. Phar-
macol. Ther. 7 (1993) 317–321.
32. A. Mathews and G. R. Bailie, Acute renal failure and hyperkalemia associated with triamterene
and indomethacin, Vet. Hum. Toxicol. 28 (1986) 224–225.
33. M. Harkonen and S. Ekblom-Kullberg, Reversible deterioration of renal function after diclofe-
nac in patient receiving triamterene, Br. Med. J. 293 (1986) 698–699.
34. T. W. B. Gehr, D. A. Sica, B. W. Steiger and C. Marshall, Interaction of triamterene-hydrochloro-
thiazide (T-H) and ibuprofen (I), Clin. Pharmacol. Ther. 47 (1990) 200–203.
35. K. N. Barker, E. A. Flynn, G. A. Pepper, D. W. Bates and R. L. Mikeal, Medication errors ob-
served in 36 health care facilities, Arch. Intern. Med. 162 (2002) 1897–1903.
36. J. E. Fontan, V. Maneglier, V. X. Nguyen, C. Loirat and F. Brion, Medication errors in hospitals:
computerised unit dose drug dispensing system versus ward stock distribution system, Pharm.
World Sci. 25 (2003) 112–117.
166
V. Ba~i} Vrca et al.: Prescribing medication errors in hospitalised patients: A prospective study, Acta Pharm. 55 (2005) 157–167.
S A @ E T A K
Propisiva~ke medikacijske pogre{ke za hospitalizirane bolesnike:
Prospektivna studija
VESNA BA^I]-VRCA, MIRA BE]IREVI]-LA]AN, VELIMIR BO@IKOV i MLADEN BIRU[
Svrha ove prospektivne studije je ispitivanje pojavnosti i vrsta medikacijskih pogre-
{aka u propisivanju i prevenciji njihovog nastanka. Podaci ispitivanja odnose se na 4951
propisani lijek, u razdoblju od 25 tjedana 2002. godine. Ispitivane medikacijske pogre{ke
definirane su kao: pogre{na doza, pogre{an interval doziranja, dupliciranje terapije, te
interakcija lijekova. Pojavnost medikacijskih pogre{aka propisivanja na ispitivanom uzorku,
uklju~uju}i sve teoretski mogu}e interakcije lijekova, iznosila je 14.7%. Me|utim, kako je
samo 8 interakcija (od ukupno 356 teoretski mogu}ih) ocijenjeno klini~ki zna~ajnim, ukupan
broj medikacijskih pogre{aka iznosio je 379 (od 4951 zapisa), {to odgovara pojavnosti od
7.7%. Pogre{ka doziranja lijeka bila je naj~e{}a vrsta uo~enih medikacijskih pogre{aka.
Utvr|ena je velika razlika izme|u incidencije teoretski mogu}ih i klini~ki zna~ajnih in-
terakcija lijekova (7.2 vs. 0.2%). Nu`an je kriti~ki pristup procjeni dostupnih podataka
vezanih za interakcije lijekova. Rezultati na{eg istra`ivanja upu}uju na nu`nost sustav-
nog nadzora propisane terapije, koji bi se mogao osigurati primjenom sustava raspodjele
jedini~ne terapije. U Hrvatskoj bi se trebao uspostaviti program pra}enja medikacijskih
pogre{aka, kako u bolnicama tako i na nacionalnoj razini.
Klju~ne rije~i: interakcije lijekova, medikacijske pogre{ke, propisivanje lijekova, prospektivna studija
Klini~ka bolnica Dubrava, Zagreb
Farmaceutsko-biokemijski fakultet, Zagreb
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